{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:08:49Z","timestamp":1781939329294,"version":"3.54.5"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jdcr.2023.05.004","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T04:15:40Z","timestamp":1684210540000},"page":"13-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Pembrolizumab-induced lichenoid dermatitis treated with dupilumab"],"prefix":"10.1016","volume":"37","author":[{"given":"Jonathan J.","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunsuh","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Damsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Vesely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jdcr.2023.05.004_bib1","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2023.05.004_bib2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jamaoncol.2021.4318","article-title":"Management of cutaneous immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors: a systematic review","volume":"8","author":"Nadelmann","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.jdcr.2023.05.004_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2021.100021","article-title":"Cytokine RNA in situ hybridization permits individualized molecular phenotyping in biopsies of psoriasis and atopic dermatitis","volume":"1","author":"Wang","year":"2021","journal-title":"JID Innov"},{"issue":"2","key":"10.1016\/j.jdcr.2023.05.004_bib4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jdcr.2023.05.004_bib5","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/bjd.21781","article-title":"Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients","volume":"187","author":"Nikolaou","year":"2022","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jdcr.2023.05.004_bib6","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jdcr.2023.05.004_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/DAD.0000000000000688","article-title":"Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features","volume":"39","author":"Tetzlaff","year":"2017","journal-title":"Am J Dermatopathol"},{"issue":"2","key":"10.1016\/j.jdcr.2023.05.004_bib8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jdcr.2023.05.004_bib9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/cup.14242","article-title":"Immune cell subsets in interface cutaneous immune-related adverse events associated with anti-PD-1 therapy resemble acute graft versus host disease more than lichen planus","volume":"49","author":"Almodovar Cruz","year":"2022","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jdcr.2023.05.004_bib10","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/exd.14226","article-title":"The inflammation in cutaneous lichen planus is dominated by IFN-\u03b3 and IL-21. A basis for therapeutic JAK1 inhibition","volume":"30","author":"Pietschke","year":"2021","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jdcr.2023.05.004_bib11","first-page":"E8","article-title":"Dupilumab for the treatment of lichen planus","volume":"107","author":"Pousti","year":"2021","journal-title":"Cutis"},{"issue":"1","key":"10.1016\/j.jdcr.2023.05.004_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512623001534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512623001534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:25:53Z","timestamp":1762475153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512623001534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":12,"alternative-id":["S2352512623001534"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2023.05.004","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab-induced lichenoid dermatitis treated with dupilumab","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2023.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}